Aclasta Gets EU Approval

Just a quicky from PharmaLive. This should really improve adherence - if they go to the MD on time!

Switzerland's Novartis AG said today the EU has approved Aclasta the first once-yearly treatment for women with postmenopausal osteoporosis. The drug was approved by the FDA in August under the name of Reclast. Last month a study showed the drug used by elderly patients who have had a hip fracture reduced deaths by 28 percent and new fractures by 35 percent over a two-year period.